|Articles|September 16, 2013
What is Misunderstood about RBM
A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials
Advertisement
A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials
This video is part of a series of conversations on
For more videos of Marc Buyse, see also:
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Ziihera Combinations Show Significant Survival Benefits in Phase III HER2+ GEA Trial
2
Tailoring Recruitment Strategies Across Platforms and Patient Populations
3
ACT Brief: Digital Recruitment Strategies, Tremfya’s Long-Term PsA Results, and Agentic AI’s Enterprise Impact
4
Long-Term APEX Trial Data Reinforce Tremfya’s Sustained Psoriatic Arthritis Control and Structural Protection
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
